CAMBRIDGE, Mass., Jan. 10,
2025 /PRNewswire/ -- MetaVia Inc.
(Nasdaq: MTVA), a clinical-stage biotechnology company focused
on transforming cardiometabolic diseases, today announced that it
is holding an Advisory Committee meeting today, at the
9th Annual MASH-TAG 2025 Conference, to discuss the
previously announced positive top-line 16-week results from the
two-part Phase 2a clinical trial of DA-1241, a novel
G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with
presumed metabolic dysfunction-associated steatohepatitis (MASH).
The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in
Park City, Utah. Members of
MetaVia's management and clinical team will be available in the
Exhibit Hall at the Conference to discuss the results of the Phase
2a clinical trial of DA-1241.
A copy of the presentation will be available on the Events and
Presentations section of the MetaVia website.
About MetaVia
MetaVia Inc. is a clinical-stage
biotechnology company focused on transforming cardiometabolic
diseases. The company is currently developing DA-1726 for the
treatment of obesity, and is developing DA-1241 for the treatment
of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726
is a novel oxyntomodulin (OXM) analogue that functions as a
glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor
(GCGR) dual agonist. OXM is a naturally-occurring gut hormone that
activates GLP1R and GCGR, thereby decreasing food intake while
increasing energy expenditure, thus potentially resulting in
superior body weight loss compared to selective GLP1R agonists.
DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist
that promotes the release of key gut peptides GLP-1, GIP, and PYY.
In pre-clinical studies, DA-1241 demonstrated a positive effect on
liver inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic inflammation, and
liver fibrosis, while also improving glucose control.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H.
Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/metavia-to-hold-advisory-committee-meeting-at-the-9th-annual-mash-tag-2025-conference-302347510.html
SOURCE MetaVia Inc.
